C. Teunissen

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

Disease-modifying therapies and biomarker-based diagnostic frameworks will fundamentally altered the clinical diagnosis and management of Alzheimer's disease. Diagnosis is increasingly anchored in the biological evidence of pathology rather than clinical presentation alone, with implications for treatment eligibility,...

Lysosomal Expression Profile in Plasma Associates with Disease Severity in Parkinson's Disease.

BACKGROUND Parkinson's disease (PD) is a clinically and biologically heterogeneous neurodegenerative disorder, driven by multiple mechanisms among which are lysosomal and mitochondrial dysfunction. Here, we explored blood-based lysosomal and mitochondrial profiles in relation to PD diagnosis and severity. METHODS Pla...

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

A dual‐domain framework is proposed in which tau‐targeted therapies are evaluated using complementary measures of aggregated tau burden and biologically defined soluble tau states, and treatment‐induced increases should be considered favorable only when they accompany aggregate reduction and evidence of a less pathogen...

Anti-CD20 B cell depletion is associated with elevated mucosal-originating circulating regulatory IgA B cells in multiple sclerosis.

It is found that anti-CD20 B cell depletion was associated with increased frequencies of regulatory mucosal-derived IgA-producing B cells in the periphery and CSF, together with increased B cell receptor clonal overlap between mucosal and systemic compartments, indicating enhanced trafficking of IgA B cells from gut mu...

Agreement between clinical diagnosis and blood biomarkers of Alzheimer's disease in a real-world peripheral memory clinic

In a peripheral real-world memory clinic setting the BBMs demonstrated high concordance with clinically diagnosed dementia due to AD, suggesting utility of BBMs in peripheral memory clinic practice, in patients with suspected dementia.

Neuroplasticity and immune system are related to altered grey matter networks: a cohort study in sporadic Alzheimer’s disease

Grey matter network topology is altered in Alzheimer’s disease and these alterations are related to cognitive decline, which suggests that preserving cognitive function in the presence of amyloid and prevention of dementia A+ may require therapies that strengthen synapses and targets the innate immune system in additio...